Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs
Open Access
- 11 October 2022
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-12
Abstract
Tuberculosis is a major global cause of both mortality and financial burden mainly in low and middle-income countries. Given the significant and ongoing rise of drug-resistant strains of Mycobacterium tuberculosis within the clinical setting, there is an urgent need for the development of new, safe and effective treatments. Here the development of a drug-like series based on a fused dihydropyrrolidino-pyrimidine scaffold is described. The series has been developed against M. tuberculosis lysyl-tRNA synthetase (LysRS) and cellular studies support this mechanism of action. DDD02049209, the lead compound, is efficacious in mouse models of acute and chronic tuberculosis and has suitable physicochemical, pharmacokinetic properties and an in vitro safety profile that supports further development. Importantly, preliminary analysis using clinical resistant strains shows no pre-existing clinical resistance towards this scaffold.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1066891, OPP1191579, INV-010616, INV-004761, INV-004709, OPP 1177930, OPP1129600)
- Bill and Melinda Gates Foundation
- Wellcome Trust (100195/Z/12/Z)
- Bill and Melinda Gates Foundation
- Bill and Melinda Gates Foundation
- Bill and Melinda Gates Foundation
- Bill and Melinda Gates Foundation
- Bill and Melinda Gates Foundation
- Division of Intramural Research
This publication has 40 references indexed in Scilit:
- Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite CladosporinCell Host & Microbe, 2012
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011
- REFMAC5 for the refinement of macromolecular crystal structuresActa Crystallographica Section D Structural Biology, 2011
- Overview of theCCP4 suite and current developmentsActa Crystallographica Section D Structural Biology, 2011
- Validation of isoleucine utilization targets in Plasmodium falciparumProceedings of the National Academy of Sciences, 2011
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Inhibition of Mammalian Mitochondrial Protein Synthesis by OxazolidinonesAntimicrobial Agents and Chemotherapy, 2006